| Literature DB >> 27694551 |
Orimisan Samuel Adekolujo1,2, Shourya Tadisina1,2, Ujwala Koduru1,2, Jill Gernand1, Susan Jane Smith1,2, Radhika Ramani Kakarala1,2.
Abstract
The effect of marital status (MS) on survival varies according to cancer type and gender. There has been no report on the impact of MS on survival in male breast cancer (MBC). This study aims to determine the influence of MS on tumor stage at diagnosis and survival in MBC. Men with MBC ≥18 years of age in the SEER database from 1990 to 2011 were included in the study. MS was classified as married and unmarried (including single, divorced, separated, widowed). Kaplan-Meier method was used to estimate the 5-year cancer-specific survival. Multivariate regression analyses were done to determine the effect of MS on presence of Stage IV disease at diagnosis and on cancer-specific mortality. The study included 3,761 men; 2,647 (70.4%) were married. Unmarried men were more often diagnosed with Stage IV MBC compared with married (10.7% vs. 5.5%, p < .001). Unmarried men (compared with married) were significantly less likely to undergo surgery (92.4% vs. 96.7%, p < .001). Overall unmarried males with Stages II, III, and IV MBC have significantly worse 5-year cancer-specific survival compared with married. On multivariate analysis, being unmarried was associated with increased hazard of death (HR = 1.43, p < .001) and increased likelihood of Stage IV disease at diagnosis ( OR = 1.96, p < .001). Unmarried males with breast cancer are at greater risk for Stage IV disease at diagnosis and poorer outcomes compared with married males.Entities:
Keywords: male breast cancer; marital status; survival
Mesh:
Year: 2016 PMID: 27694551 PMCID: PMC5675311 DOI: 10.1177/1557988316669044
Source DB: PubMed Journal: Am J Mens Health ISSN: 1557-9883
Baseline Clinicopathological Characteristics of Patients.
| Variable | Married, | Unmarried, |
|
|---|---|---|---|
|
| 64.8 (11.97) | 65.0 (13.36) | .743 |
|
| |||
| Caucasian | 2,239 (84.6) | 866 (77.7) | |
| African American | 240 (9.1) | 212 (19.0) | |
| Others | 168 (6.3) | 36 (3.2) | |
|
| 48,537.65 | 47,445.46 | .006 |
|
| |||
| Metropolitan | 2,352 (88.9) | 987 (88.6) | .343 |
| Non-metropolitan | 282 (10.7) | 117 (10.5) | |
| Unknown | 13 (0.5) | 10 (0.9) | |
|
| |||
| Well differentiated | 317 (12.0) | 129 (11.6) | .305 |
| Moderately differentiated | 1,252 (47.3) | 511 (45.9) | |
| Poorly differentiated | 880 (33.2) | 367 (32.9) | |
| Undifferentiated | 28 (1.1) | 15 (1.3) | |
| Unknown | 170 (6.4) | 92 (8.3) | |
|
| |||
| Ductal | 2,216 (83.7) | 909 (81.6) | .165 |
| Lobular | 36 (1.4) | 11 (1.0) | |
| Papillary | 67 (2.5) | 36 (3.2) | |
| Inflammatory | 9 (0.3) | 6 (0.5) | |
| Mucinous | 44 (1.7) | 13 (1.2) | |
| Others | 275 (10.4) | 139 (12.5) | |
|
| |||
| ER+PR+ | 2,189 (82.7) | 916 (82.2) | .642 |
| ER+PR− | 297 (11.2) | 132 (11.8) | |
| ER−PR+ | 26 (1.0) | 15 (1.3) | |
| ER−PR− | 135 (5.1) | 51 (4.6) | |
|
| |||
| I | 961 (36.3) | 287 (25.8) | <.001 |
| II | 1,100 (41.6) | 456 (40.9) | |
| III | 440 (16.6) | 252 (22.6) | |
| IV | 146 (5.5) | 119 (10.7) | |
|
| |||
| None | 1,893 (71.5) | 762 (68.4) | .066 |
| Radiation | 706 (26.7) | 322 (28.9) | |
| Unknown | 48 (1.8) | 30 (2.7) | |
|
| |||
| Had surgery | 2,559 (96.7) | 1,029 (92.4) | <.001 |
| Recommended, not performed | 18 (0.7) | 21 (1.9) | |
| Not recommended | 70 (2.6) | 64 (5.7) | |
Note. ER = estrogen receptor; PR = progesterone receptor.
Figure 1.Kaplan–Meier curves of the effect of marital status on cancer-specific survival for all stages.
Figure 4.Kaplan–Meier curves of the effect of marital status on cancer-specific survival by decade.
Figure 2.Kaplan–Meier curves of the effect of marital status on cancer-specific survival by stage.
Figure 3.Kaplan-Meier curves of the effect of marital status on overall survival by stage.
Multivariate Logistic Regression Analysis for Predictors of Stage IV Disease at Diagnosis.[a]
| Variable |
| |
|---|---|---|
|
| ||
| ≥65 | Ref. | |
| >65 | 1.18 [0.91, 1.53] | .223 |
|
| ||
| Caucasian | Ref. | |
| African American | 1.41 [0.99, 1.98] | .052 |
| Others | 1.00 [0.53, 1.75] | .999 |
|
| ||
| Married | Ref. | |
| Unmarried | 1.96 [1.50, 2.56] | <.001 |
|
| ||
| Well differentiated | Ref. | |
| Moderately differentiated | 2.43 [1.31, 5.05] | .009 |
| Poorly differentiated | 3.92 [2.12, 8.11] | <.001 |
| Undifferentiated | 1.60 [0.24, 6.51] | .561 |
| Unknown | 8.15 [4.14, 17.60] | <.001 |
|
| ||
| ER+PR+ | Ref. | |
| ER+PR− | 1.96 [1.38, 2.74] | <.001 |
| ER−PR+ | 2.76 [1.01, 6.41] | .029 |
| ER−PR− | 2.69 [1.72, 4.12] | <.001 |
|
| ||
| Ductal | Ref. | |
| Lobular | 0.43 [0.07, 1.46] | .252 |
| Papillary[ | — | |
| Inflammatory[ | — | |
| Mucinous | 0.73 [0.17, 2.10] | .613 |
| Others | 1.60 [1.12, 2.25] | .009 |
Note. OR = odds ratio; CI = confidence interval; ER = estrogen receptor; PR = progesterone receptor.
Final model chosen by backward selection using the likelihood ratio test. bNo patients with Stage IV in these categories.
Multivariate Cox Regression Analysis for Cancer-Specific Mortality.[a]
| Variable | HR [95% CI] |
|
|---|---|---|
|
| ||
| ≥65 | Ref. | |
| <65 | 0.81 [0.69, 0.96] | .012 |
|
| ||
| Caucasian | Ref. | |
| African American | 1.18 [0.95, 1.47] | .144 |
| Others | 0.85 [0.56, 1.28] | .426 |
|
| ||
| Married | Ref. | |
| Unmarried | 1.43 [1.21, 1.70] | <.001 |
|
| 0.55 [0.38, 0.81] | .002 |
|
| ||
| Well differentiated | Ref. | |
| Moderately differentiated | 1.52 [1.01, 2.29] | .046 |
| Poorly differentiated | 2.02 [1.33, 3.04] | <.001 |
| Undifferentiated | 2.59 [1.32, 5.10] | .006 |
| Unknown | 1.96 [1.23, 3.14] | .005 |
|
| ||
| ER+PR+ | Ref. | |
| ER+PR− | 1.34 [1.09, 1.66] | .006 |
| ER−PR+ | 1.34 [0.73, 2.46] | .346 |
| ER−PR− | 1.72 [1.28, 2.31] | <.001 |
|
| ||
| I | Ref. | |
| II | 2.77 [2.06, 3.72] | <.001 |
| III | 6.04 [4.46, 8.19] | <.001 |
| IV | 25.23 [17.99, 35.38] | <.001 |
|
| ||
| Ductal | Ref. | |
| Lobular | 1.07 [0.47, 2,42] | .870 |
| Papillary | 0.24 [0.08, 0.76] | .015 |
| Inflammatory | 0.52 [0.16, 1.63] | .262 |
| Mucinous | 0.49 [0.16, 1.53] | .219 |
| Others | 0.71 [0.54, 0.93] | .013 |
|
| ||
| Had surgery | Ref. | |
| Recommended but not performed | 2.21 [1.40, 3.50] | <.001 |
| Not recommended | 2.41 [1.77, 3.28] | <.001 |
Note. HR = hazard ratio; CI = confidence interval; ER = estrogen receptor; PR = progesterone receptor.
Final model chosen by backward selection using the likelihood ratio test.